Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISION-AF: Safety of Aflibercept in Indian DME Patients
NCT05511038Phase 4Completed
- Sponsor
- Bayer
- Start
- Aug 2022
- Primary completion
- Apr 2024
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in diabetic macular edema (DME), sponsored by Bayer. Started Aug 2022; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05511038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05511038.